Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
0.4254
Dollar change
+0.0004
Percentage change
0.09
%
Index- P/E- EPS (ttm)-0.55 Insider Own47.09% Shs Outstand128.42M Perf Week0.09%
Market Cap54.63M Forward P/E- EPS next Y-0.28 Insider Trans0.42% Shs Float67.95M Perf Month-1.98%
Income-49.50M PEG- EPS next Q-0.08 Inst Own9.06% Short Float0.39% Perf Quarter63.62%
Sales0.65M P/S84.05 EPS this Y35.74% Inst Trans11.31% Short Ratio0.30 Perf Half Y-19.43%
Book/sh0.10 P/B4.08 EPS next Y6.62% ROA-102.25% Short Interest0.26M Perf Year-61.33%
Cash/sh0.27 P/C1.56 EPS next 5Y- ROE-595.47% 52W Range0.25 - 1.22 Perf YTD43.43%
Dividend Est.- P/FCF- EPS past 5Y-18.22% ROI-194.55% 52W High-65.13% Beta0.49
Dividend TTM- Quick Ratio1.53 Sales past 5Y50.93% Gross Margin-227.37% 52W Low70.16% ATR (14)0.04
Dividend Ex-Date- Current Ratio1.53 EPS Y/Y TTM-15.71% Oper. Margin-6198.78% RSI (14)49.94 Volatility5.83% 10.26%
Employees85 Debt/Eq2.40 Sales Y/Y TTM38.27% Profit Margin-7569.42% Recom1.00 Target Price5.00
Option/ShortYes / Yes LT Debt/Eq0.90 EPS Q/Q-461.70% Payout- Rel Volume0.28 Prev Close0.43
Sales Surprise17.24% EPS Surprise86.11% Sales Q/Q-27.35% EarningsMar 13 BMO Avg Volume864.95K Price0.43
SMA201.77% SMA50-4.16% SMA200-22.59% Trades Volume238,275 Change0.09%
Date Action Analyst Rating Change Price Target Change
Oct-04-22Downgrade Oppenheimer Outperform → Perform
Jul-18-22Initiated H.C. Wainwright Buy $16
May-02-22Initiated Canaccord Genuity Buy $10
Sep-28-21Initiated Oppenheimer Outperform $20
Mar-19-24 08:30AM
Mar-15-24 08:00AM
Mar-13-24 09:30AM
08:00AM
Mar-07-24 08:00AM
08:00AM Loading…
Feb-29-24 08:00AM
Feb-22-24 08:00AM
Feb-05-24 02:30PM
Jan-24-24 08:30AM
Jan-10-24 09:00AM
Jan-08-24 07:00AM
Jan-03-24 04:25PM
Dec-22-23 03:00PM
Dec-21-23 07:46AM
07:00AM
07:00AM Loading…
07:00AM
Dec-19-23 09:00AM
Dec-15-23 03:00PM
Dec-14-23 08:36AM
Dec-12-23 08:30AM
Dec-08-23 02:19PM
Nov-23-23 09:00AM
Nov-14-23 08:30AM
Nov-09-23 09:00AM
Nov-07-23 08:57AM
08:00AM
Oct-31-23 08:30AM
Oct-26-23 08:30AM
Oct-19-23 08:30AM
Oct-17-23 08:30AM
09:00AM Loading…
Oct-11-23 09:00AM
Oct-06-23 02:15PM
Oct-05-23 10:00AM
Sep-29-23 03:00PM
08:30AM
Sep-28-23 08:00AM
Sep-27-23 09:00AM
Sep-25-23 04:00PM
07:00AM
Aug-30-23 08:20AM
Aug-29-23 07:00AM
Aug-14-23 08:00AM
Aug-02-23 07:00AM
Jun-28-23 11:19AM
07:13AM
Jun-26-23 08:00AM
Jun-21-23 09:20AM
07:20AM
Jun-16-23 08:00AM
Jun-15-23 04:38PM
04:29PM
07:00AM
May-25-23 08:00AM
May-12-23 04:00PM
Apr-25-23 04:05PM
Apr-11-23 08:00AM
Mar-16-23 09:46AM
Mar-13-23 07:00AM
Mar-09-23 06:30AM
Mar-08-23 04:10PM
Mar-07-23 08:00AM
Mar-06-23 07:00AM
Feb-27-23 07:00AM
Feb-13-23 07:00AM
Jan-11-23 08:00AM
Dec-27-22 04:01PM
Dec-12-22 08:00AM
Nov-28-22 08:00AM
Nov-07-22 08:00AM
Oct-31-22 08:00AM
Oct-03-22 08:00AM
Sep-30-22 04:12PM
Sep-21-22 07:00AM
Aug-30-22 07:00AM
Aug-15-22 07:00AM
07:00AM
Aug-12-22 04:01PM
Jul-19-22 07:00AM
Jul-14-22 07:00AM
Jun-27-22 07:00AM
Jun-02-22 07:00AM
Jun-01-22 07:00AM
May-19-22 07:30AM
May-16-22 08:00AM
May-09-22 08:00AM
May-04-22 11:29AM
Apr-01-22 07:00AM
Mar-14-22 07:00AM
Mar-11-22 07:00AM
Mar-03-22 07:00AM
Feb-24-22 07:00AM
Feb-18-22 07:00AM
Feb-14-22 07:00AM
Feb-01-22 07:00AM
Jan-26-22 05:14AM
Jan-18-22 07:00AM
Dec-15-21 07:00AM
Dec-13-21 07:00AM
Dec-12-21 06:34AM
Dec-10-21 07:00AM
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MATLIN DAVID JDirectorNov 10 '23Buy0.41250,002102,5017,043,686Nov 13 07:48 AM
Stevens John HenryDirectorJun 26 '23Buy0.80316,455253,164800,204Jun 27 02:13 PM
Etherington Robert DeeChief Executive OfficerJun 26 '23Buy0.8125,00020,25025,000Jun 27 08:07 AM
Ugwumba ChidozieResigned as director 2/15/2023Jun 16 '23Buy0.807,500,0006,000,00013,018,908Sep 08 04:33 PM
Mosca AlisonDirectorJun 16 '23Buy0.802,394,3751,915,5003,238,375Jun 20 11:02 AM
MATLIN DAVID JDirectorJun 16 '23Buy0.801,500,0001,200,0006,793,684Jun 20 07:57 AM
Gay JonathonDirectorJun 16 '23Buy0.80105,62584,500105,625Jun 20 09:50 AM